ÂÜÀòÂÒÂ×

Dan Chevallard is a seasoned finance executive with extensive experience in the biotechnology sector. Currently serving as Chief Financial Officer at LENZ Therapeutics since March 2024, Dan previously held multiple leadership roles, including Chief Operating Officer and Chief Financial Officer at Viracta Therapeutics, Inc., and Chief Financial Officer at Regulus Therapeutics. Dan's career includes significant positions at Prometheus Laboratories, where responsibilities spanned corporate accounting, financial reporting, and management of large R&D budgets. Additional experience includes senior roles at Ernst & Young, focusing on IPO efforts and Sarbanes-Oxley compliance. Dan holds a Bachelor of Arts in Accounting from the University of San Diego.